Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide, directly related to the progressive increase in body weight and obesity. The accumulation of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response and oxidative stress in hepatocytes and alteration of the circulating lipid and glycaemic profile. However, to date, there are no effective pharmacological treatments for patients with NAFLD. Lifestyle changes and dietary modifications aimed at weight loss are the best current alternatives; therefore, new approaches should be considered. Resveratrol, a natural polyphenol of the stilbene group, is a potential candidate for the management of NAFLD for its anti-inflammatory, antioxidant properties, and calorie restriction-like effects.
Methods: In this review, the available information on the potential therapeutic effects of resveratrol on NAFLD, found mainly in animal models and in some clinical trials, is summarizes.
Results: In vitro and animal model studies have shown beneficial effects of resveratrol treatment on NAFLD. Resveratrol reduces the hepatic accumulation of lipids and improves lipid and glycaemic metabolism. Some of the mechanisms of action are the signalling pathways of AMP-activated protein kinase, sirtuin 1 and nuclear factor κB. However, the results obtained in clinical trials are inconclusive.
Conclusion: Although preclinical trials have shown promising results of resveratrol against NALFD, the lack of clear results in clinical trials makes it necessary to conduct more studies with a larger number of patients and for a longer time.
Keywords: Inflammation, non-alcoholic fatty liver disease, polyphenols, resveratrol, sirtuin 1, steatosis.
Current Pharmaceutical Design
Title:Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease
Volume: 27 Issue: 22
Author(s): Silvia Tejada, Xavier Capó, Catalina Mª Mascaró, Margalida Monserrat-Mesquida, Mª Magdalena Quetglas-Llabrés, Antoni Pons, Josep A. Tur and Antoni Sureda*
Affiliation:
- Research Group on Community Nutrition and Oxidative Stress (NUCOX), Health Research Institute of the Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Balearic Islands,Spain
Keywords: Inflammation, non-alcoholic fatty liver disease, polyphenols, resveratrol, sirtuin 1, steatosis.
Abstract:
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide, directly related to the progressive increase in body weight and obesity. The accumulation of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response and oxidative stress in hepatocytes and alteration of the circulating lipid and glycaemic profile. However, to date, there are no effective pharmacological treatments for patients with NAFLD. Lifestyle changes and dietary modifications aimed at weight loss are the best current alternatives; therefore, new approaches should be considered. Resveratrol, a natural polyphenol of the stilbene group, is a potential candidate for the management of NAFLD for its anti-inflammatory, antioxidant properties, and calorie restriction-like effects.
Methods: In this review, the available information on the potential therapeutic effects of resveratrol on NAFLD, found mainly in animal models and in some clinical trials, is summarizes.
Results: In vitro and animal model studies have shown beneficial effects of resveratrol treatment on NAFLD. Resveratrol reduces the hepatic accumulation of lipids and improves lipid and glycaemic metabolism. Some of the mechanisms of action are the signalling pathways of AMP-activated protein kinase, sirtuin 1 and nuclear factor κB. However, the results obtained in clinical trials are inconclusive.
Conclusion: Although preclinical trials have shown promising results of resveratrol against NALFD, the lack of clear results in clinical trials makes it necessary to conduct more studies with a larger number of patients and for a longer time.
Export Options
About this article
Cite this article as:
Tejada Silvia , Capó Xavier , Mascaró Mª Catalina , Monserrat-Mesquida Margalida , Quetglas-Llabrés Mª Magdalena , Pons Antoni , Tur A. Josep and Sureda Antoni *, Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease, Current Pharmaceutical Design 2021; 27 (22) . https://dx.doi.org/10.2174/1381612826666200417165801
DOI https://dx.doi.org/10.2174/1381612826666200417165801 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review
Current Drug Metabolism Determination of Parameters of Oxidative Stress in vitro Models of Neurodegenerative Diseases-A Review
Current Clinical Pharmacology Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Controlling the Flow of Energy: Inhibition and Stimulation of the Creatine Transporter
Current Enzyme Inhibition Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?
Current Drug Targets New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry C. elegans as Model for Drug Discovery
Current Topics in Medicinal Chemistry Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Enzyme Inhibitors
Current Bioactive Compounds Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design